{"entity":{"id":"nct07458204","kind":"trial","name":"Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer","aka":["EPPIL"],"tldr":"A phase 2 trial in triple-negative breast cancer, run by Institut Jean-Godinot, not yet recruiting.","summary":"Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT07458204 by Institut Jean-Godinot, with a registry enrolment figure of 760 participants, started 2026-10-01 and due to reach its primary completion in 2031-10-01. Interventions recorded: LVB infiltration. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* with histologically confirmed triple-negative breast cancer\". Sites: France. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07458204","url":"https://clinicaltrials.gov/study/NCT07458204"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07458204","phase":"2","setting":"Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer","sponsor":"Institut Jean-Godinot","enrolled":760,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07458204/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}